OurCoronaTimes.com

Forum

Positive data from ...
 
Share:
Notifications
Clear all

Positive data from Israel for COVID-19 treatment using PLX cells  

  RSS

zorba
(@zorba)
Member Admin
Joined: 9 months ago
Posts: 15
24/04/2020 5:53 pm  

 Pluristem Reports Preliminary Data from Its COVID-19 Compassionate Use Program

 By HospiMedica International staff writers
Posted on 10 Apr 2020

   

Pluristem Therapeutics Inc. (Haifa, Israel), a regenerative medicine company developing a platform of novel biological therapeutic products, has released positive preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristem’s PLX cells, in three medical centers in Israel…. PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties that induce the immune system’s natural regulatory T cells and M2 macrophages, and thus may prevent or reverse the dangerous over-activation of the immune system. Accordingly, PLX cells may potentially reduce the incidence and/or severity of COVID-19 pneumonia and pneumonitis leading hopefully to a better prognosis for the patients…. For Pluristem’s compassionate use program, all the seven patients approved for treatment with PLX cells exhibited, prior to treatment, respiratory failure due to ARDS, which is a major cause of mortality and required mechanical ventilation in an ICU. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure, indicating critical disease and poor prognosis. Six patients completed one week follow up, while the seventh patient was treated on April 5 2020. Preliminary data following treatment with PLX cells demonstrated a 100% survival rate.


Quote
Share: